Ridgeback Biotherapeutics LP
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ridgeback Biotherapeutics LP
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
- In Vitro Diagnostics